(Q46078145)

English

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia

scientific article published on 29 May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

0 references

phase II clinical trial

0 references

endometrial carcinoma

1 reference

based on heuristic

inferred from title

author name string

Vincent Castonguay

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Stephanie Lheureux

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Stephen Welch

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Helen J Mackay

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Hal Hirte

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Gini Fleming

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

R Morgan

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Lisa Wang

8

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Chantale Blattler

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Percy S Ivy

10

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Amit M Oza

11

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

language of work or name

0 references

publication date

29 May 2014

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Gynecologic Oncology

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

134

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

274-280

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Treatment options for advanced endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Recent advances in systemic therapy for advanced endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Contemporary management of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

What is the role of chemotherapy in endometrial cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

The angiogenic ?vascular endothelial growth factor/flk-1(KDR) receptor? pathway in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Angiogenesis in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Sunitinib: from rational design to clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.05.016

7 January 2021

Identifiers

10.1016/J.YGYNO.2014.05.016

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24882554

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46078145&oldid=2091170412"